Abstract:Introduction: Nanoparticles have the advantages of improving the solubility of poorly water-soluble drugs, facilitating the drug across biological barriers, and reducing macrophage phagocytosis in pulmonary drug delivery. However, nanoparticles have a small aerodynamic particle size, which makes it difficult to achieve optimal deposition when delivered directly to the lungs. Therefore, delivering nanoparticles to the lungs effectively has become a popular research topic. Methods: Nanoaggregate microparticles were used as a pulmonary drug delivery strategy for the improvement of the bioavailability of cyclosporine A (CsA). The nanoaggregate microparticles were prepared with polyvinyl pyrrolidone (PVP) as the excipient by combining the anti-solvent method and spray drying process. The physicochemical properties, aerodynamic properties, in vivo pharmacokinetics and inhalation toxicity of nanoaggregate microparticles were systematically evaluated. Results: The optimal nanoparticles exhibited mainly spherical shapes with the particle size and zeta potential of 180.52 nm and -19.8 mV. The nanoaggregate microparticles exhibited irregular shapes with the particle sizes of less than 1.6 µm and drug loading (DL) values higher than 70%. Formulation NM-2 as the optimal nanoaggregate microparticles was suitable for pulmonary drug delivery and probably deposited in the bronchiole and alveolar region, with FPF and MMAD values of 89.62% and 1.74 μm. In addition, inhaled NM-2 had C max and AUC0-∞ values approximately 1.7-fold and 1.8-fold higher than oral cyclosporine soft capsules (Neoral®). The inhalation toxicity study suggested that pulmonary delivery of NM-2 did not result in lung function damage, inflammatory responses, or tissue lesions. Conclusion: The novel nanoaggregate microparticles for pulmonary drug delivery could effectively enhance the relative bioavailability of CsA and had great potential for clinical application.

Study on Preparation Conditions for Polylactide Nanoparticles Loaded Cyclosporine A and Its Oral Bioavailability in Rats

[Preparation of Cyclosporine A Ph Sensitive Nanoparticles and Oral Pharmacokinetics in Rats].

Enhancement of Oral Bioavailability of Cyclosporine A: Comparison of Various Nanoscale Drug-Delivery Systems.

Studies on Preparation of Cyclosporine A-loaded Polycyanoacrylate Nanoparticles

[Relative Bioavailability of Cyclosporine A-loaded Hydroxypropyl Methylcellulose Phthalate Nanoparticles for Oral Administration in Rats].

Preparation and Evaluation of Poly(Ethylene Glycol)–Poly(Lactide) Micelles As Nanocarriers for Oral Delivery of Cyclosporine A

Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration

Ph-Sensitive Nanoparticles for Improving the Oral Bioavailability of Cyclosporine A.

Pharmacokinetics and Enhanced Oral Bioavailability in Beagle Dogs of Cyclosporine A Encapsulated in Glyceryl Monooleate/Poloxamer 407 Cubic Nanoparticles

Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt.

Solid Self-Nanoemulsifying Cyclosporine A Pellets Prepared by Fluid-Bed Coating: Stability and Bioavailability Study

Two Novel Freeze-Dried Ph-Sensitive Cyclosporine A Nanoparticles: Preparation, in Vitro Drug Release, and in Vivo Absorption Enhancement Effects

Effect of Surface Modification on the Uptake of Polylactic Acid Nanoparticles Loading Cyclosporine A by Cells in Vitro and on the Body Distribution in Vivo

Comparing the Pharmacokinetic Characteristics of Cyclosporine A Loaded Polylactic Acid Nanoparticles Colloid Injections with Sandoz Sandimmun ○R by Intravenous Administration to Rabbits

Sylysia 350/Eudragit S100 solid nanomatrix as a promising system for oral delivery of cyclosporine A.

Long-term Studies on the Stability and Oral Bioavailability of Cyclosporine A Nanoparticle Colloid

Cyclosporin A-loaded poly(ethylene glycol)-b-poly(d,l-lactic acid) micelles: preparation, in vitro and in vivo characterization and transport mechanism across the intestinal barrier.

Solid Self-Nanoemulsifying Cyclosporin A Pellets Prepared by Fluid-Bed Coating: Preparation, Characterization and in Vitro Redispersibility

Influence of suspending agents on relative bioavailability of cyclosporine A-loaded HPMCP nanoparticles for oral administration to rats

Amphiphilic Poly(L-Aspartic Acid) Copolymer Nanoparticles for Cyclosporine A Delivery

Highly Drug-Loaded Nanoaggregate Microparticles for Pulmonary Delivery of Cyclosporin A